Immunovia Publ (Sweden) Performance
| IMMNOV Stock | SEK 0.47 0.02 4.08% |
The company retains a Market Volatility (i.e., Beta) of 0.41, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immunovia Publ's returns are expected to increase less than the market. However, during the bear market, the loss of holding Immunovia Publ is expected to be smaller as well. At this point, Immunovia publ AB has a negative expected return of -0.37%. Please make sure to check out Immunovia Publ's potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Immunovia publ AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immunovia publ AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 468.5 M | |
| Total Cashflows From Investing Activities | -23.8 M | |
| Free Cash Flow | -176.8 M |
Immunovia |
Immunovia Publ Relative Risk vs. Return Landscape
If you would invest 64.00 in Immunovia publ AB on October 21, 2024 and sell it today you would lose (17.00) from holding Immunovia publ AB or give up 26.56% of portfolio value over 90 days. Immunovia publ AB is generating negative expected returns and assumes 5.6191% volatility on return distribution over the 90 days horizon. Simply put, 50% of stocks are less volatile than Immunovia, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Immunovia Publ Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunovia Publ's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunovia publ AB, and traders can use it to determine the average amount a Immunovia Publ's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0658
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMMNOV |
Estimated Market Risk
| 5.62 actual daily | 50 50% of assets are less volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immunovia Publ is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunovia Publ by adding Immunovia Publ to a well-diversified portfolio.
Immunovia Publ Fundamentals Growth
Immunovia Stock prices reflect investors' perceptions of the future prospects and financial health of Immunovia Publ, and Immunovia Publ fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunovia Stock performance.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (201.30) % | |||
| Current Valuation | 536.89 M | |||
| Shares Outstanding | 22.63 M | |||
| Price To Earning | (57.93) X | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 683.47 X | |||
| Revenue | 844 K | |||
| EBITDA | (135.47 M) | |||
| Cash And Equivalents | 359.85 M | |||
| Cash Per Share | 18.42 X | |||
| Total Debt | 27.16 M | |||
| Debt To Equity | 7.80 % | |||
| Book Value Per Share | 13.09 X | |||
| Cash Flow From Operations | (152.65 M) | |||
| Earnings Per Share | (7.80) X | |||
| Total Asset | 493.81 M | |||
About Immunovia Publ Performance
By analyzing Immunovia Publ's fundamental ratios, stakeholders can gain valuable insights into Immunovia Publ's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Immunovia Publ has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunovia Publ has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Immunovia AB , a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. Immunovia AB was founded in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 46 people.Things to note about Immunovia publ AB performance evaluation
Checking the ongoing alerts about Immunovia Publ for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunovia publ AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunovia publ AB generated a negative expected return over the last 90 days | |
| Immunovia publ AB has high historical volatility and very poor performance | |
| Immunovia publ AB has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 844 K. Net Loss for the year was (166.63 M) with profit before overhead, payroll, taxes, and interest of 15.81 M. | |
| Immunovia publ AB has accumulated about 359.85 M in cash with (152.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.42, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 36.0% of the company shares are held by company insiders |
- Analyzing Immunovia Publ's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunovia Publ's stock is overvalued or undervalued compared to its peers.
- Examining Immunovia Publ's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunovia Publ's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunovia Publ's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunovia Publ's stock. These opinions can provide insight into Immunovia Publ's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Immunovia Stock analysis
When running Immunovia Publ's price analysis, check to measure Immunovia Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovia Publ is operating at the current time. Most of Immunovia Publ's value examination focuses on studying past and present price action to predict the probability of Immunovia Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovia Publ's price. Additionally, you may evaluate how the addition of Immunovia Publ to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |